Davunetide (also known as AL-108, NAP, or NAPvasop) was a neuroprotective peptide developed by Allon Therapeutics Inc. that was evaluated in a Phase 2 clinical trial for Progressive Supranuclear Palsy (PSP). The trial failed to meet its primary endpoint, providing important lessons about neuroprotective strategies in tauopathies[@clinicaltrialsgov][@allon].
Davunetide (also known as AL-108, NAP, or NAPvasop) was a neuroprotective peptide developed by Allon Therapeutics Inc. that was evaluated in a Phase 2 clinical trial for Progressive Supranuclear Palsy (PSP). The trial failed to meet its primary endpoint, providing important lessons about neuroprotective strategies in tauopathies[@clinicaltrialsgov][@allon].
Davunetide (also known as AL-108, NAP, or NAPvasop) was a neuroprotective peptide developed by Allon Therapeutics Inc. It was evaluated in a Phase 2 clinical trial for Progressive Supranuclear Palsy (PSP). The trial failed to meet its primary endpoint, providing important lessons about neuroprotective strategies in tauopathies.[@clinicaltrialsgov][@allon]
| Parameter | Details |
|-----------|---------|
| Drug Name | Davunetide (AL-108, NAP) |
| Sponsor | Allon Therapeutics Inc. |
| ClinicalTrials.gov ID | NCT00490781 |
| Phase | Phase 2 |
| Status | Completed (Failed) |
| Duration | 12 months |
| Enrollment | Approximately 300 participants |
| Randomization | 1:1 davunetide:placebo |
| Blinding | Double-blind |
| Endpoint Type | Measures |
|--------------|----------|
| Primary | Change in PSP Rating Scale (PSPRS) |
| Secondary | MMSE, ADAS-Cog, CGI-C |
| Exploratory | CSF biomarkers, MRI volumetrics |
Davunetide was a synthetic peptide derived from the neuroprotective protein Activity-Dependent Neuroprotective Protein (ADNP). The drug was designed to:
The peptide was administered intranasally, which was designed to bypass the blood-brain barrier and deliver the drug directly to the brain.[@allon]
PSP is characterized by tau pathology affecting the brainstem and subcortical structures. The neuroprotective mechanism of davunetide was considered relevant because:
The Phase 2 trial failed to demonstrate efficacy:
The trial's failure to meet its primary endpoint can be analyzed from multiple perspectives:
| Factor | Impact | Analysis |
|--------|--------|----------|
| Effect size | Small treatment effect | Insufficient power |
| Variability | PSPRS high variability | Sample size |
| Placebo | Natural progression | Disease trajectory |
| Dropouts | Missing data | ITT analysis |
Post-hoc analyses may include:
The FDA Fast Track designation reflected the high unmet need in PSP:
The davunetide failure had several impacts:
| Year | Milestone | Status |
|------|----------|--------|
| 2005 | Preclinical neuroprotection demonstrated | Complete |
| 2006 | Phase 1 safety completed | Complete |
| 2007 | Phase 2a MCI/AD initiated | Complete |
| 2008 | Phase 2a results: Mixed signals | Complete |
| 2009 | PSP trial initiated | Complete |
| 2010 | Fast Track designation received | Complete |
| 2012 | PSP trial failed primary endpoint | Complete |
| 2013 | Program discontinued | Complete |
The neuroprotective therapy field in tauopathies includes:
| Agent | Company | Mechanism | Status | Indication |
|-------|--------|-----------|--------|------------|
| Davunetide | Allon | Microtubule stabilization | Failed | PSP, AD |
| Taltirelin | Takeda | TRH analog | Phase 2 | PSP |
| Lithium | Various | GSK-3β inhibition | Phase 2 | PSP |
| Neflamapimod | EIP Pharma | p38 MAPK inhibition | Phase 2 | PSP |
| Masitinib | AB Science | Tyrosine kinase | Phase 3 | ALS |
Allon Therapeutics was a biopharmaceutical company focused on developing neuroprotective therapies:
The intranasal route was chosen for several reasons[@insua2007]:
| Factor | Consideration |
|--------|---------------|
| BBB penetration | Direct nose-to-brain delivery |
| Reduced systemic exposure | Lower side effects |
| Non-invasive | Patient acceptance |
| Rapid onset | Quick brain entry |
Despite the rationale, challenges included:
Other delivery approaches that could be explored:
| Route | Advantages | Disadvantages |
|-------|-------------|---------------|
| Intravenous | Precise dosing | BBB penetration |
| Intraventricular | Direct CNS | Invasive |
| Intrathecal | Spinal cord target | Surgical |
| Intranasal | Non-invasive | Variable |
| Oral | Patient-friendly | Poor CNS penetration |
The davunetide trial failure reflects broader challenges:
| Factor | Explanation |
|--------|-------------|
| Advanced pathology | Established neurodegeneration may be irreversible |
| Multiple mechanisms | Single-target approaches may be insufficient |
| Biomarker gaps | Cannot confirm target engagement |
| Timing | Too late in disease course |
Based on lessons learned:
Similar neuroprotective strategies still being explored in PSP include:
| Year | Event |
|------|-------|
| 2005 | Preclinical studies demonstrate neuroprotective activity |
| 2007 | Phase 1 trial initiated |
| 2009 | Phase 2 trial in PSP initiated |
| 2012 | Trial failed to meet primary endpoint |
| 2013 | Allon Therapeutics ceased operations |
| 2014-2025 | Program not pursued further |
The FDA granted Fast Track designation to davunetide for PSP in 2010, acknowledging the high unmet need in this indication. Despite this designation, the negative Phase 2 results led to program discontinuation.
Davunetide is derived from ADNP (Activity-Dependent Neuroprotective Protein), a naturally occurring neuroprotective protein:
The davunetide trial highlights a critical challenge in neuroprotective drug development—the inability to directly measure target engagement in the brain:
| Challenge | Impact | Mitigation |
|-----------|--------|----------|
| BBB penetration unknown | Cannot confirm brain exposure | CSF sampling, PET ligands |
| Microtubule binding | Cannot measure in vivo | Surrogate biomarkers |
| Functional endpoint | Clinical readouts delayed | Longer trials |
| Mechanism validation | Cannot confirm MOA | Post-mortem studies |
Future neuroprotective trials could incorporate:
| Biomarker Type | Purpose | Example |
|-----------------|---------|----------|
| CSF biomarkers | Target engagement | Tau, p-tau, NFL |
| Neuroimaging | Structural changes | MRI volumetrics |
| PET ligands | Protein burden | Tau PET |
| Genetic | Patient stratification | Risk variants |
In the absence of direct target engagement measures, alternative approaches include:
The davunetide PSP Phase 2 trial represents an illustrative case study in CNS drug development:
| Parameter | Expected | Actual |
|-----------|----------|--------|
| Primary endpoint | PSPRS improvement | No difference |
| Secondary endpoints | Cognitive benefit | No benefit |
| Safety | Acceptable profile | Well-tolerated |
| Efficacy | Disease modification | Failed |
The negative result was unexpected given positive preclinical data, highlighting the challenge of translating animal model findings to human neurodegenerative disease.
Multiple factors contributed to the trial failure:
Despite the negative outcome, the program contributed lasting value:
The trial occurred during a period of intense investment in neuroprotective therapies:
Current approaches building on lessons learned:
| Approach | Learning Applied | Status |
|-----------|-------------------|--------|
| Tau ASOs | Target specific production | Phase 1/2 |
| Gene therapy | Continuous protein expression | Preclinical |
| Combination | Multi-target approaches | Phase 2 |
| Biomarker-driven | Patient selection | Emerging |
| Agent | Target | Route | Stage | Indication |
|-------|--------|-------|-------|------------|
| Davunetide | Microtubule | Intranasal | Phase 2 | Failed |
| Taltirelin | TRH analog | Oral | Phase 2 | PSP |
| Lithium | GSK-3β | Oral | Phase 2 | PSP |
| Neflamapimod | p38 MAPK | Oral | Phase 2 | PSP |
| AZP2006 | ApoE | Oral | Phase 1 | PSP |
The preclinical program included multiple animal model studies:
| Study | Model | Findings |
|-------|-------|----------|
| Stroke models | MCAO rats | Reduced infarct size |
| PD models | 6-OHDA rats | Neuroprotection |
| AD models | 3xTg mice | Improved cognition |
| Aging | Aged rodents | Cognitive improvement |
The translation from animal models to human trials faced challenges:
| Factor | Animal Models | Human Trials | Gap |
|--------|--------------|-------------|-----|
| Disease stage | Acute injury | Chronic disease | Significant |
| Pathology | Induced | Progressive | Significant |
| Delivery | Injection | Intranasal | Moderate |
| Outcome | Survival | Function | Moderate |
Key differences between preclinical species and humans:
The trial incorporated exploratory biomarker analyses:
| Biomarker | Sampling | Findings |
|-----------|----------|----------|
| Total tau | CSF | Elevated in PSP |
| Phosphorylated tau | CSF | Increased with progression |
| Neurofilament light | CSF | Correlated with atrophy |
| Amyloid-beta 40/42 | CSF | Not a primary factor |
Neuroimaging was integrated to understand treatment effects:
| Modality | Purpose | Finding |
|----------|---------|----------|
| MRI brainstem | Regional volumetrics | Progression in disease regions |
| MR spectroscopy | Metabolite levels | Limited sensitivity |
| DAT imaging | Dopaminergic integrity | Not treatment-related |
The imaging findings confirmed disease progression despite treatment, suggesting inadequate biological activity of davunetide at the achieved brain concentrations.
The davunetide failure affected the broader neuroprotective drug development landscape:
| Impact | Area | Effect |
|--------|------|-------|
| Funding | Venture capital | Decreased |
| Pipeline | Company pipelines | Reduced |
| Partnerships | Pharma interest | Diminished |
| Trials | Clinical programs | Consolidation |
The failure also influenced academic research directions:
Future neuroprotective approaches may explore:
The Phase 2 trial design reflected the challenges inherent in neuroprotective drug development for chronic neurodegenerative diseases:
| Design Element | Rationale | Limitation |
|---------------|-----------|-----------|
| 12-month duration | Sufficient for progression | May be too short |
| PSPRS primary | Standard PSP measure | Insensitive to change |
| 1:1 randomization | Balanced groups | Standard |
| Double-blind | Reduce bias | Cannot confirm compliance |
The trial was designed to detect a clinically meaningful difference:
Comprehensive analyses after trial completion:
The trial represented significant investment:
| Cost Category | Estimate |
|--------------|----------|
| Preclinical | $20-30M |
| Clinical operations | $40-60M |
| Manufacturing | $10-15M |
| Regulatory | $5-10M |
| Total | $75-115M |
The davunetide Phase 2 trial in PSP, while ultimately unsuccessful, represents an important chapter in neurodegeneration drug development:
| Dimension | Assessment |
|-----------|-----------|
| Scientific contribution | Advanced understanding of microtubule biology |
| Clinical infrastructure | Established PSP trial network |
| Lessons learned | Critical insights for future trials |
| Field impact | Influenced neuroprotective strategies |
The failure of davunetide and similar neuroprotective approaches points toward a new paradigm:
The neuroscience community continues to build on these lessons, with ongoing programs applying the insights gained from this and similar trials.
The Phase 2 clinical trial of davunetide (AL-108) in PSP represents an important case study in neuroprotective drug development for tauopathies. The trial failure provides critical lessons for the field:
Key Learnings:
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses:
The following diagram shows the key molecular relationships involving Davunetide (AL-108) PSP Trial discovered through SciDEX knowledge graph analysis: